Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246493 · ClinicalTrials.gov registry record
Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)
A clinical trial, sponsored by National Institute on Aging (NIA).
- Terminated
- Registry status
- 495
- Enrollment target
NCT00246493: Clinical Trial study, sponsored by National Institute on Aging (NIA).
NCT00246493 is a clinical trial that was terminated before completion, run by National Institute on Aging (NIA). The registered enrollment target is 495 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00246493 was terminated before completion, sponsored by National Institute on Aging (NIA).
- TERMINATED
- Registry status
- 495 participants
- Enrollment target
Study Summary
The prevalence, incidence, and severity of atherosclerotic disease all markedly increase with age. Basic experimental and observational data demonstrate that aging magnifies the pathologic and clinical consequences of established risk factors and is the most potent individual risk factor for coronary atherosclerosis and for adverse outcomes following an ischemic event. These findings suggest that normal aging alters the vascular substrate so as to promote the development and progression of atherosclerosis. The age-associated changes in vascular structure and function include an increase in central vascular stiffness, intimal proliferation, and endothelial dysfunction. The major hypothesis is that the above alterations in vascular substrate (i.e. vascular age) are an important determinant of the age associated increased likelihood for the development and progression of coronary atherosclerotic disease. This program will non-invasively characterize vascular age and atherosclerotic burden in BLSA participants and individuals with successful aging, i.e. those with no or minimal evidence of coronary atherosclerotic disease, and those with premature, clinically evident coronary artery disease. It will repeat measures of vascular age and atherosclerotic burden three years after the first assessment. By examining the impact of vascular age on the initial extent and the progression of atherosclerotic burden over a two to three-year period, it will test the hypothesis that vascular age is an important determinant of the ageassociated increase in atherosclerotic disease....
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2004-06-22 |
| Est. Completion | 2017-11-01 |
Why NCT00246493 stopped before completion
NCT00246493 is an observational study that tracks outcomes without assigning an intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00246493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00246493 about?
NCT00246493 is a clinical study titled "Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)". The prevalence, incidence, and severity of atherosclerotic disease all markedly increase with age. Basic experimental and observational data demonstrate that aging magnifies the pathologic and clinical consequences of established risk factors and is the most potent individual risk factor for coronar...
What is the current status of trial NCT00246493?
This trial is currently terminated. The enrollment target is 495 participants. The study started on 2004-06-22. Estimated completion is 2017-11-01.
Who is sponsoring clinical trial NCT00246493?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI